Journal of Cystic Fibrosis 2025
11 papers
The 2025 edition of the Journal of Cystic Fibrosis highlights research on the evolving microbiological landscape and the clinical implications of highly effective modulator therapy (HEMT). A primary focus involves the study of airway infections, including the epidemiology of *Pseudomonas aeruginosa* and the genomic adaptation of *Mycobacterium abscessus*. Research also examines the relationship between chronic inhaled antibiotic use and the emergence of new pathogens, alongside investigations into how specific genetic drivers influence bacterial survival in the post-HEMT lung.
Beyond microbiology, the journal explores shifts in clinical management, such as the discontinuation of physiotherapy in adult patients responding well to modulator treatments. Technical developments include the use of resonant acoustic rheometry for non-invasive mucus characterization, while healthcare delivery is addressed through reports on establishing satellite clinics. Notable contributors include Jonathan D. Cogen, Marianne S. Muhlebach, and John J. LiPuma. These studies collectively reflect a transition toward optimizing care and understanding pathogen behavior in an era of advanced cystic fibrosis therapies.
Top Authors
| Author | Papers |
|---|---|
| Dessi P. Zaharieva | 1 |
| Dick B.M. Botteldooren | 1 |
| Hamid Alinejad-Rokny | 1 |
| N. Jon Shah | 1 |
| Oliver Biggs Clarke | 1 |